China biotech IPO China’s Biotech IPO Comeback — Sparked by Innogen’s 285% Debut China’s biotech IPOs roar back in 2025, led by Innogen’s 285% debut and gains from Duality and Leads Biolabs; U.S. IPOs like Caris and Omada rise more cautiously.